PIZENSY
Peaklactitol
NDAORALSOLUTION
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PIZENSY (lactitol) is an oral solution approved in February 2020 for gastrointestinal indications. Lactitol is a disaccharide that acts as an osmotic laxative, drawing water into the intestinal lumen to promote bowel movements. It is used to treat constipation and related conditions in patients requiring gentle, non-stimulant therapeutic options.
Peak11.0 years to LOE
Peak lifecycle stage with 11.1 years of patent protection indicates stable commercial operations; team size and hiring likely moderate with focus on market maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PIZENSY offers stable, long-term career continuity in a mature therapeutic franchise through 2037. Roles emphasize market maintenance, payer relationships, and specialty pharmacy positioning rather than launch intensity or pipeline innovation.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.